切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2018, Vol. 14 ›› Issue (01) : 44 -50. doi: 10.3877/cma.j.issn.1673-5250.2018.01.007

所属专题: 文献

论著

人乳头瘤病毒E6/E7 mRNA检测在宫颈上皮内瘤变1预后中的预测价值
张璐1, 张永欣1, 张友忠2,()   
  1. 1. 264001 山东,烟台市烟台山医院妇科
    2. 250000 济南,山东大学齐鲁医院妇科
  • 收稿日期:2017-08-24 修回日期:2018-01-08 出版日期:2018-02-01
  • 通信作者: 张友忠

Predictive values of human papillomavirus E6/E7 mRNA test in the prognosis of cervical epithelial neoplasm 1

Lu Zhang1, Yongxin Zhang1, Youzhong Zhang2,()   

  1. 1. Department of Gynecology, Yantaishan Hospital of Yantai, Yantai 264001, Shandong Province, China
    2. Department of Gynecology, Qilu Hospital of Shandong University, Jinan 250000, Shandong Province, China
  • Received:2017-08-24 Revised:2018-01-08 Published:2018-02-01
  • Corresponding author: Youzhong Zhang
  • About author:
    Corresponding author: Zhang Youzhong, Email:
引用本文:

张璐, 张永欣, 张友忠. 人乳头瘤病毒E6/E7 mRNA检测在宫颈上皮内瘤变1预后中的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2018, 14(01): 44-50.

Lu Zhang, Yongxin Zhang, Youzhong Zhang. Predictive values of human papillomavirus E6/E7 mRNA test in the prognosis of cervical epithelial neoplasm 1[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2018, 14(01): 44-50.

目的

探讨人乳头瘤病毒(HPV) E6/E7 mRNA检测在宫颈上皮内瘤变(CIN)1患者预后中的预测价值。

方法

选取2013年7月至2014年10月,于烟台市烟台山医院妇科经阴道镜下宫颈活组织病理学检查,首次确诊为CIN1的107例患者为研究对象。所有受试者均于首次确诊为CIN1前1个月内,同时接受宫颈液基薄层细胞学检查(TCT)、HPV DNA基因分型及HPV E6/E7 mRNA检测;于阴道镜下宫颈活组织病理学检查确诊为CIN1后,对其进行为期2年的随访,每6个月随访1次。随访检查项目包括宫颈TCT、HPV DNA基因分型及HPV E6/E7 mRNA检测,并对可疑病变者予以阴道镜下宫颈活组织病理学检查。根据随访结束时受试者的TCT、HPV DNA基因分型、HPV E6/E7 mRNA检测结果及阴道镜下宫颈活组织病理学检查结果,将本研究受试者分为转阴组与持续或进展组。采用χ2检验,对2组受试者的HPV E6/E7 mRNA阳性率进行比较;采用Mann-Whitney U秩和检验,对2组HPV E6/E7 mRNA表达水平进行比较;计算3种宫颈病变筛查方法对于预测CIN1预后的敏感度和特异度;绘制HPV E6/E7 mRNA表达水平预测CIN1预后的受试者工作特征(ROC)曲线,计算ROC曲线下面积(ROA-AUC),根据约登指数最大原则,确定HPV E6/E7 mRNA表达水平预测CIN1预后的最佳临界值,同时计算其敏感度和特异度。本研究遵循的程序符合烟台市烟台山医院伦理委员会所制定的标准,获得该伦理委员会批准,并与受试者均签署临床研究知情同意书。

结果

①根据随访结束时受试者的TCT、HPV DNA基因分型、HPV E6/E7 mRNA检测结果及阴道镜下宫颈活组织病理学检查结果,将本研究受试者分为转阴组(n=63,随访结束时,TCT、HPV DNA基因分型及HPV E6/E7 mRNA检测结果均为正常,或阴道镜下宫颈活组织病理学检查结果为阴性),持续或进展组(n=44,随访结束时,阴道镜下宫颈活组织病理学检查结果为CIN1及以上)。2组患者的年龄等一般临床资料比较,差异均无统计学意义(P>0.05)。②持续或进展组受试者确诊为CIN1时的HPV E6/E7 mRNA阳性率及其中位表达水平分别为61.9%(39/63)和3 738.4 copy/mL,转阴组分别为81.8%(36/44)和583.5 copy/mL,持续或进展组HPV E6/E7 mRNA阳性率及其中位表达水平均显著高于转阴组,并且差异均有统计学意义(χ2=4.901,P=0.027;U=821.000,P<0.001)。③HPV-16/18阳性患者CIN持续或进展率为50.8%(31/61),显著高于HPV-16/18阴性者的28.3%(13/46),并且差异有统计学意义(χ2=5.512,P=0.019)。HPV E6/E7 mRNA阳性患者CIN持续或进展率为48.0%(36/75),显著高于HPV E6/E7 mRNA阴性者的25.0%(8/32),并且差异亦有统计学意义(χ2=4.901,P=0.027)。TCT、HPV DNA基因分型及HPV E6/E7 mRNA定性检测对于预测CIN1患者预后的敏感度分别为50.0%、70.5%、81.8%,特异度分别为66.7%、52.4%、38.1%。④HPV E6/E7 mRNA表达水平预测CIN1患者预后的ROC曲线分析结果显示,HPV E6/E7 mRNA表达水平预测CIN1持续或进展的ROC-AUC为0.704(95%CI:0.601~0.806,P<0.001),HPV E6/E7 mRNA表达水平预测CIN持续或进展的最佳临界值为2 724.0 copy/mL,此时其预测CIN1持续或进展的敏感度为54.5%,特异度为81.0%。

结论

HPV E6/E7 mRNA定性检测结果对于预测CIN1患者预后的敏感度较高,而其定量检测结果对于预测CIN1患者预后的特异度较高。HPV E6/E7 mRNA检测可能对CIN1患者预后的预测具有一定临床价值。

Objective

To evaluate the predictive values of human papilloma virus (HPV) E6/E7 mRNA test in the prognosis of patients with cervical intraepithelial neoplasia (CIN) 1.

Methods

From July 2013 to October 2014, a total of 107 cases of patients who were initially diagnosed as CIN1 by pathologic results of colposcopic cervical biopsy in Department of Gynecology, Yantaishan Hospital of Yantai were selected as research subjects. All subjects received cervical ThinPrep liquid-based cytology test (TCT), HPV DNA genotyping test and HPV E6/E7 mRNA test within one month prior to initial diagnosis of CIN1. Two-year follow-ups and once every six months were conducted on all subjects, including the re-examination of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA test. And cervical biopsies were conducted on suspicious lesions. According to the results of TCT, HPV DNA genotyping test, HPV E6/E7 mRNA test and colposcopic cervical biopsy at the end of follow-up, all subjects were enrolled into negative group and continuous or progressive group, respectively. Chi-square test was used to compare the positive rates of HPV E6/E7 mRNA between two groups. Mann-Whitney U rank sum test was used to compare expression levels of HPV E6/E7 mRNA between two groups. The sensitivities and specificities of these three cervical screening methods in predicting the prognosis of CIN1 were calculated respectively. Then receiver operator characteristic (ROC) curve of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was drawn, and the area under ROC curve (ROC-AUC) was calculated.The optimal critical value of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was obtained when the Youden index reaching the maximum value.And its sensitivity and specificity were calculated. This study was approved by the Ethics Committee of Human Beings in Yantaishan Hospital of Yantai and informed consent of clinical research has been signed with every subject.

Results

①According to the results of TCT, HPV DNA genotyping test, HPV E6/E7 mRNA test and colposcopic cervical biopsy at the end of follow-up, all subjects were enrolled into negative group (n=63, the results of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA test all were normal or the colposcopic cervical biopsy result was negative at the end of follow-up) and continuous or progressive group (n=44, the colposcopic cervical biopsy result was CIN1 or higher grade at the end of follow-up). There were no statistically significant differences between two groups in basic clinical data such as age and etc. (P>0.05). ②The positive rate of HPV E6/E7 mRNA and median expression level of HPV E6/E7 mRNA were 61.9% (39/63) and 3 738.4 copy/mL in continuous or progressive group, which were significantly higher than those in negative group (81.8%, 36/44) and 583.5 copy/mL, respectively), and both the differences were statistically significant (χ2=4.901, P=0.027; U=821.000, P<0.001). ③According to the results of two-year follow-up, the continuous or progressive rate of CIN in patients with HPV-16/18 positive was 50.8% (31/61), which was significantly higher than that in patients with HPV-16/18 negative (28.3%, 13/46), and the difference was statistically significant (χ2=5.512, P=0.019). The continuous or progressive rate of CIN in patients with HPV E6/E7 mRNA positive was 48.0% (36/75), which was significantly higher than that in patients with HPV E6/E7 mRNA negative (25.0%, 8/32), and the difference was statistically significant (χ2=4.901, P=0.027). The sensitivities of TCT, HPV DNA genotyping test and HPV E6/E7 mRNA qualitative test in predicting the prognosis of CIN1 were 50.0%, 70.5%, 81.8%, and the specificities were 66.7%, 52.4%, 38.1%, respectively. ④The results of ROC curve analysis of HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 showed that the ROC-AUC was 0.704 (95%CI: 0.601-0.806, P<0.001), and the optimal critical of value HPV E6/E7 mRNA expression level in predicting the prognosis of CIN1 was 2 724.0 copy/mL, and the sensitivity of HPV E6/E7 mRNA expression level in predicting continuous or progression of CIN was 54.5%, and the sensitivity was 81.0%.

Conclusions

The sensitive of HPV E6/E7 mRNA qualitative test in predicting the prognosis of CIN1 is relatively high, while the specificity of HPV E6/E7 mRNA quantitative test in predicting the prognosis of CIN1 is relatively high. HPV E6/E7 mRNA test may has clinical values in predicting the prognosis of patients with CIN1.

表1 2组患者确诊为CIN1时的HPV E6/E7 mRNA阳性率及其表达水平比较
表2 不同宫颈病变筛查方法对CIN1患者预后的预测效果分析[例数(%)]
图1 HPV E6/E7 mRNA表达水平预测CIN1预后的ROC曲线
[1]
魏丽惠,沈丹华,赵方辉,等. 中国子宫颈癌筛查及异常管理相关问题专家共识(二)[J]. 中国妇产科临床杂志,2017, 18(3):286-288.
[2]
Binnicker MJ, Pritt BS, Duresko BJ, et al. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results[J]. J Clin Microbiol, 2014, 52(10):3763-3768.
[3]
徐亚丽,高国生,高志斌,等. 人乳头状瘤病毒E6/E7 mRNA检测在不同程度宫颈病变中的应用与分析[J]. 中国卫生检验杂志,2016, 26(22):3260-3262.
[4]
黄雅琴,孟晓华,高阳,等. 人乳头状瘤病毒E6/E7m RNA检测筛查宫颈病变的价值[J]. 中国卫生检验杂志,2015, 25(1):90-91, 94.
[5]
吴慧卿,叶凤如,黄玉玲,等. HPV E6/E7 mRNA检测在年轻女性宫颈癌筛查及宫颈疾病诊治中的应用价值[J]. 中国妇幼保健,2016, 31(14):2817-2819.
[6]
王璐,王晨阳,王武亮,等. 高危型人乳头瘤病毒E6/E7 mRNA检测对宫颈高度鳞状上皮内病变诊断及随访价值研究[J]. 中国实用妇科与产科杂志,2016, 32(6):580-582.
[7]
Nayar R, Wilbur DC. The Pap test and Bethesda 2014[J]. Cancer Cytopathol, 2015, 123(5):271-281.
[8]
杜彩英,李芳. 人乳头瘤病毒DNA及E6/E7 mRNA检测在宫颈病变诊断中的比较研究[J]. 中国优生与遗传杂志,2015, 23(4):38-40.
[9]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-E386.
[10]
庞晓庆,郝敏,赵卫红,等. 宫颈上皮内瘤变管理的进展[J]. 肿瘤学杂志,2014, 20(3):181-185.
[11]
Zhang L, Li Q, Zhao M, et al. Discrepancies between biopsy-based and excision-based grading of cervical intraepithelial neoplasia: the important role of time between excision and biopsy[J]. Int J Gynecol Pathol, 2015, 34(3):221-227.
[12]
Galarowicz B, Jach R, Kidzierska J, et al. The role of mRNA E6/E7 HPV high oncogenic risk expression in colposcopy of cervical intraepithelial neoplasia (CIN)[J]. Przegl Lek, 2012, 69(9):651-657.
[13]
宋艳萍,钱小泉,施赛欧,等. HPV E6/E7 mRNA检测在宫颈癌筛查中的应用价值[J]. 中国优生与遗传杂志,2016, 24(4):25-27, 39.
[14]
应香岚,赵湘婉,吴晨曦,等. 应用TCT标本检测高危HPV E6/E7 mRNA在宫颈病变筛查中的价值[J]. 中国卫生检验杂志,2014, 24(23):3422-3424.
[15]
李晓林,栾少红,陈龙,等. 高危型人乳头瘤病毒E6/E7 mRNA检测在宫颈病变筛查中的应用[J/CD].中华妇幼临床医学杂志(电子版), 2017, 13(2):156-161.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[7] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[8] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[9] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[10] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[11] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要